Twist Bioscience Corp Cash Flow Conversion Efficiency
Twist Bioscience Corp cash flow conversion efficiency. Based on the latest financial reports, Twist Bioscience Corp (TWST) has a cash flow conversion efficiency ratio of 0.003x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.11 Million) by net assets ($445.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Twist Bioscience Corp (2016–2025)
Cash flow conversion efficiency of Twist Bioscience Corp from 2016 to 2025. This chart illustrates how Twist Bioscience Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TWST stock price for real-time trading data and today's change.
Twist Bioscience Corp Cash Flow Conversion Ratio Explained
Twist Bioscience Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Twist Bioscience Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Twist Bioscience Corp ranked by their cash flow conversion efficiency. Also see TWST market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Founder Securities Co Ltd
SHG:601901
|
-0.087x |
|
Bid Corporation Ltd
JSE:BID
|
0.182x |
|
Ayvens SA
PA:AYV
|
0.459x |
|
Impala Platinum Holdings Ltd
JSE:IMP
|
0.047x |
|
Lotus Bakeries
BR:LOTB
|
0.090x |
|
Murphy USA Inc
NYSE:MUSA
|
0.394x |
|
Vicinity Centres
AU:VCX
|
0.028x |
|
Kesko Oyj
HE:KESKOB
|
0.103x |
Annual Cash Flow Conversion Efficiency for Twist Bioscience Corp (2016–2025)
The table below shows the annual cash flow conversion efficiency of Twist Bioscience Corp from 2016 to 2025. Review Twist Bioscience Corp free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $472.96 Million | $-47.63 Million | -0.101x | +25.73% |
| 2024-09-30 | $472.69 Million | $-64.09 Million | -0.136x | +40.67% |
| 2023-09-30 | $623.43 Million | $-142.47 Million | -0.229x | -45.03% |
| 2022-09-30 | $789.38 Million | $-124.39 Million | -0.158x | +18.46% |
| 2021-09-30 | $580.82 Million | $-112.24 Million | -0.193x | +54.32% |
| 2020-09-30 | $336.26 Million | $-142.25 Million | -0.423x | +26.84% |
| 2019-09-30 | $152.08 Million | $-87.94 Million | -0.578x | -276.03% |
| 2018-09-30 | $-201.42 Million | $-66.16 Million | 0.328x | -14.61% |
| 2017-09-30 | $-133.36 Million | $-51.30 Million | 0.385x | -23.63% |
| 2016-09-30 | $-76.61 Million | $-38.59 Million | 0.504x | -- |
About Twist Bioscience Corp
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo … Read more